Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population‐based matched‐cohort study

2019 ◽  
Vol 147 (1) ◽  
pp. 33-44
Author(s):  
Johanna Simin ◽  
Rulla M. Tamimi ◽  
Steven Callens ◽  
Lars Engstrand ◽  
Nele Brusselaers
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Cancer Risk ◽  
Hormone Therapy ◽  
Treatment Options ◽  
Population Based ◽  
Ovarian Cancer Risk ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Therapy Treatment

scholarly journals Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study

2018 ◽  
Vol 7 (5) ◽  
pp. 2153-2159 ◽  
Author(s):  
Chih-Chiang Chen ◽  
Yun-Ting Chang ◽  
Han-Nan Liu ◽  
Yi-Ju Chen
Keyword(s):  
Cohort Study ◽  
Cancer Risk ◽  
Alopecia Areata ◽  
Population Based ◽  
Matched Cohort ◽  
Matched Cohort Study

scholarly journals Nonsteroidal Anti-Inflammatory Drugs Reduce Second Cancer Risk in Patients With Breast Cancer: A Nationwide Population-Based Propensity Score-Matched Cohort Study in Taiwan

2021 ◽  
Vol 11 ◽  
Author(s):  
Yin-Che Lu ◽  
Pin-Tzu Chen ◽  
Mei-Chen Lin ◽  
Che-Chen Lin ◽  
Shi-Heng Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Propensity Score ◽  
Cancer Risk ◽  
Population Based ◽  
Matched Cohort ◽  
Second Cancer ◽  
Matched Cohort Study ◽  
Inflammatory Drugs ◽  
Second Cancer Risk

Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce mortality in patients with cancer, especially breast cancer, but their influence on second cancer risk is uncertain. This study aimed to examine whether NSAID use is associated with second cancer risk in patients with breast cancer. This population-based propensity score-matched cohort study using Taiwan’s National Health Insurance Research Database enrolled patients with newly diagnosed breast cancer (n = 7356) with and without (n = 1839) NSAID therapy from 2000 to 2009. They were followed up until the diagnosis of second cancer, death, or end of 2011. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHR). The NSAID cohort had a lower incidence rate of second cancer than the non-NSAID cohort (5.57 vs. 9.19 per 1,000 person-years), with an aHR of 0.63 (95% confidence interval (CI) 0.46–0.87). When compared with the non-NSAID cohort, the second cancer incidence was lower in patients taking non-cyclooxygenase 2 inhibitors (aHR 0.67, 95% CI 0.47–0.94) and in those receiving multiple NSAIDs during follow-up (aHR 0.55, 95% CI 0.37–0.84). A dose–response relationship existed in NSAID cumulative days. The findings demonstrate that NSAID use reduces second cancer risk in a dose-dependent manner in patients with primary breast cancer.

Mortality among older Spanish people with hip fractures: a population-based matched cohort study

2021 ◽  
Author(s):  
Alicia Gutiérrez-Misis ◽  
Rocío Queipo ◽  
María Victoria Castell ◽  
Teresa Alarcón ◽  
Rocío Menéndez-Colino ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hip Fractures ◽  
Population Based ◽  
Matched Cohort ◽  
Matched Cohort Study
Sign in / Sign up

Export Citation Format

Share Document